Related Experiment Video
Updated: May 11, 2026
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
Aza-BODIPY-Derived Fluorescent Probe for Cancer Cell Imaging and Combined PDT/PTT Applications
1, 1, Tavish Sharma1
1Department of Chemistry, Netaji Subhas University of Technology (NSUT), New Delhi, India.
Abstract:
The global health landscape continues to be challenged by cancer, prompting ongoing investigations aimed at developing treatments that are both less invasive and more effective. Photodynamic (PDT) and photothermal (PTT) treatments have gained prominence due to their efficacy in inhibiting tumors while minimizing impact on surrounding healthy tissues. The integration of these methodologies with fluorescent molecular imaging (FMI), recognized for its significant potential in early cancer detection, presents a compelling noninvasive treatment strategy. Near-infrared (NIR) fluorescent dyes, including cyanine dyes and boron-dipyrromethene (BODIPY) derivatives, along with aza-BODIPY derivatives, represent some of the most efficient organic small molecules employed in cancer FMI and phototherapy. Their robust tissue penetration, minimal light scattering, and reduced autofluorescence make these compounds highly suitable for biological applications. Aza-BODIPY, a derivative from the organoboron family of BODIPY, is notable for its exceptional spectral properties, featuring red-shifted absorption and elevated molar extinction coefficients that enhance both imaging and therapeutic outcomes. This study examines potential modifications to aza-BODIPY aimed at enhancing its effectiveness in phototherapy and cancer detection, thereby expanding its application as a versatile tool for effective cancer treatment strategies.
Insights
This study explores modifications to aza-BODIPY, a fluorescent dye, to improve its effectiveness in phototherapy and cancer detection. Enhanced aza-BODIPY offers a promising noninvasive strategy for cancer treatment and early diagnosis.
Area of Science:
- Biomedical Engineering
- Organic Chemistry
- Oncology
Background:
- Cancer remains a significant global health challenge, driving research for less invasive and more effective treatments.
- Photodynamic therapy (PDT) and photothermal therapy (PTT) show promise for tumor inhibition with minimal damage to healthy tissues.
- Fluorescent molecular imaging (FMI) is crucial for early cancer detection, and its integration with PDT/PTT offers a noninvasive treatment strategy.
Purpose of the Study:
- To investigate modifications of aza-BODIPY derivatives to enhance their utility in cancer phototherapy and detection.
- To explore the potential of advanced aza-BODIPY compounds as versatile tools for cancer treatment strategies.
Main Methods:
- Utilized near-infrared (NIR) fluorescent dyes, specifically aza-BODIPY derivatives, known for strong tissue penetration and minimal light scattering.
- Examined spectral properties of aza-BODIPY, including red-shifted absorption and high molar extinction coefficients.
- Investigated potential chemical modifications to optimize aza-BODIPY for improved imaging and therapeutic outcomes.
Main Results:
- Aza-BODIPY derivatives exhibit favorable spectral properties for biological applications in cancer imaging and phototherapy.
- Enhanced molar extinction coefficients and red-shifted absorption contribute to improved imaging and therapeutic efficacy.
- Potential modifications were identified to further boost the performance of aza-BODIPY in clinical cancer applications.
Conclusions:
- Aza-BODIPY derivatives are highly efficient organic small molecules for cancer FMI and phototherapy.
- Modifications to aza-BODIPY can significantly enhance its effectiveness in both cancer detection and treatment.
- Optimized aza-BODIPY holds promise as a versatile agent for advanced, noninvasive cancer management strategies.
